Indicator, Reagent, or Diagnostic Aid – Page 3 – Talk Bio

Actionable Insights Powered by AI

Lilly Secures Option to Acquire Radionetics for $1 Billion in Radiopharma Deal

10 months ago talkbio0Tagged Acquisition (action), Biotechnology, Eli, Eli Lilly, Neoplasms, Radionetics, Radiopharmaceuticals, Solid Neoplasm

Eli Lilly, Radionetics Oncology, Radiopharmaceuticals, G Protein-Coupled Receptors, Solid Tumors, Biotechnology, Acquisition

J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial

10 months ago talkbio0Tagged Giant Cell Arteritis, glucocorticoid-free remission, Johnson & Johnson, Phase 2 Clinical Trials, Primary Endpoint, Tremfya

Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission

Jazz Pharmaceuticals’ Essential Tremor Drug Candidate Fails to Meet Primary Endpoint in Phase IIb Trial

10 months ago talkbio0Tagged calcium channel modulator, Essential Tremor, Jazz, Phase II B Trial, Primary Endpoint

Jazz Pharmaceuticals, suvecaltamide, essential tremor, phase IIb trial, primary endpoint, calcium channel modulator

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

10 months ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials

Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings

11 months ago talkbio0Tagged biotech, IPO, Nasdaq, offerings, Radiopharmaceuticals, Telix

Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

11 months ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal

11 months ago talkbio0Tagged actinium-225, Isotope Supply, Myers, Neoplasms, Neurosecretory Systems, Radiopharmaceuticals, RayzeBio, squibb

RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors

Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome

11 months ago talkbio0Tagged Annexon, ANX005, Disability, Guillain-Barre Syndrome, Phase 3 trial, Prices, Primary Endpoint, Sharing (Social Behavior), surge

Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge

Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition

11 months ago talkbio0Tagged Acquisition (action), Aktis, Cancer Therapeutic Procedure, cellular targeting, Eli Lilly, portfolio, Radiopharmaceuticals

Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment

Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk

11 months ago talkbio0Tagged Administration occupational activities, Clinical Trials, Diabetes, Drug Industry, Eli Lilly, Insulin, insulin therapy, Nordisk, Primary Endpoint, trials, Weekly

Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.